Chemical Strategy to Translate Genetic/Epigenetic Mechanisms to Breast Cancer Therapeutics
Abstract
We have been awarded a project designed to use a molecular signature strategy to develop new therapeutics against metastatic breast cancer. As originally proposed, we have been pursuing the projects in three phases: (1) Define the molecular signature tightly linked to the gene expression program underlined the Epithelial-to-Mesenchymal Transition (EMT), (2) Conduct chemical screening by following the EMT program by using a novel pathway-centric technology we recently developed, and (3) characterize leading components identified from the screen on cell and animal models to evaluate their effects in inhibit breast cancer metastasis. The goals set for the first year are to define genes regulated by Twist, Slug, and Sip1 in a triple negative breast cancer cell line. We have accomplished all set goals. In addition, we have proceeded to design and test oligo pool to be used for chemical screening and adapt our assays in the high throughput format on our robots. We are well positioned to move to the next phase, which is to further refine the assay conditions and then conduct the proposed chemical screening.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2012
- Accession Number
- ADA562003
Entities
People
- Betty Diamond
- Xiang-dong Fu
Organizations
- University of California, San Diego